Episcleral Brachytherapy for the Treatment of Wet AMD

ClinicalTrials.gov ID: NCT02988895

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02988895. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 13, 2026, 1:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective Study of Episcleral Brachytherapy for the Treatment of Neovascular Age-related Macular Degeneration

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a prospective, multi-site, safety and feasibility study of the SalutarisMD SMD-DA system for retrobulbar minimally invasive episcleral brachytherapy device in patients receiving and not responding to anti-VEGF therapy for nAMD. The trial will be open label and non-randomized. The study intervention is a one-time intervention and requires no alteration to the standard of care during the follow-up period.

Study identification

NCT ID: NCT02988895
Recruitment status: Not listed
Study type: Interventional
Phase: Not applicable
Lead sponsor: Salutaris Medical Devices, Inc.; Industry
Enrollment: 11 participants

Conditions and interventions

Conditions

Macular Degeneration, Choroidal Neovascularization

Interventions

episcleral brachytherapy Radiation

Radiation

Eligibility (public fields only)

Age range: 50 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Aug 1, 2017 (Actual)
Primary completion: May 26, 2023 (Actual)
Completion: May 2025 (Estimated)
Last update posted: Aug 30, 2023

2017 – 2025

United States locations

U.S. sites: 2
U.S. states: 2
U.S. cities: 2

Facility	City	State	ZIP	Site status
Retina Consultants of Hawaii	‘Aiea	Hawaii	96701	—
University Retina	Oak Forest	Illinois	60452	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02988895, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 30, 2023 · Synced Nov 13, 2026